A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma
- Status
- RECRUITING
- Phase
- PHASE3
Clinical Trials Related to Ibrutinib
Related studies linked through entity extraction aliases.
Ibrutinib Followed by BR (Bendamustine and Rituximab) as a Time-Limited Therapy for Waldenström Macroglobulinemia
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1
A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)
- Status
- RECRUITING
- Phase
- PHASE1
Mosunetuzumab for CLL MRD Clearance
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
CAR-T-cell Treatment for Untreated High Risk MANtle Cell Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Benefits of Individual Physical Activity Intervention on Health-related Quality of Life in Participants With Chronic Lymphocytic Leukemia
- Status
- RECRUITING
- Phase
- N/A
Ibrutinib for the Prevention of Chronic Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant
- Status
- TERMINATED
- Phase
- PHASE2
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
- Status
- RECRUITING
- Phase
- PHASE3
Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia
- Status
- RECRUITING
- Phase
- PHASE2
Genetically Risk-Stratified Venetoclax, Ibrutinib, Rituximab (± Navitoclax) in Relapsed/Refractory Mantle Cell Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Real World Data on Ibrutinib Use in PCNSL Rel/Ref
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- N/A
Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation
- Status
- RECRUITING
- Phase
- PHASE2
A Study of Ibrutinib With Rituximab in Relapsed or Refractory Mantle Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma
- Status
- WITHDRAWN
- Phase
- PHASE3
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Status
- RECRUITING
- Phase
- PHASE3